COVID-19 Updates

Children’s Healthcare of Atlanta Announces New Hire at the Aflac Cancer and Blood Disorders Center


ATLANTA (Sept. 18, 2018) – Children’s has announced that Jason Fangusaro, MD, a Pediatric Hematolgoist/Oncologist at Children's Healthcare of Atlanta, has been named Director of the Developmental Therapeutics Program at the Aflac Cancer and Blood Disorders Center of Children's, effective yesterday. Dr. Fangusaro is also an Associate Professor at the Emory University School of Medicine and the Carter S. Martin Endowed Chair. He will be a member of the neuro-oncology team and Medical Director of the Clinical Research Office.

“I am thrilled and honored to lead the developmental therapeutics team at the Aflac Cancer and Blood Disorders Center,” Dr. Fangusaro said. “The current team is amazingly strong, and I am humbled to be able to work alongside this group of physicians, nurses, researchers and support staff. Together, I know we can make the Developmental Therapeutics Program a leader within the national pediatric oncology community.”

The Developmental Therapeutics Program focuses on the creation of new treatments for children with cancer and blood disorders, with the hope that new drugs, new combinations of drugs or new ways of administering drugs will lead to better outcomes for our young patients.

“We are excited to have Dr. Fangusaro on board to continue to grow our Developmental Therapeutics Program, which represents hope for so many patients,” said Douglas K. Graham, MD, PhD, Director of the Aflac Cancer and Blood Disorders Center. “He brings invaluable expertise and experience to the role, and we look forward to him leading our team as we pursue the goal of innovative treatments and, ultimately, a better life for our young patients.”

Dr. Fangusaro has specialty training in treating children with central nervous system malignancies, including brain and spinal cord tumors. His primary area of research is the development of early phase clinical trials, novel therapeutics and relevant biologic correlates in an effort to improve survival outcomes and minimize toxicities. Within pediatric brain tumors, his research has focused on two main areas: low-grade gliomas (LGG) and central nervous system (CNS) germ cell tumors (GCTs).

He is a member of the Children’s Oncology Group (COG) Brain Tumor Steering Committee, serves as Vice Chair of the Pediatric Brain Tumor Consortium (PBTC) and partners with the pharmaceutical industry on investigator-initiated trials. Dr. Fangusaro, a member of the LGG and CNS GCT international consensus panels, also serves as the principal investigator and co-investigator on numerous national trials.

Aflac Cancer and Blood Disorders Center of Children’s

The Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta is a national leader among childhood cancer, hematology, and blood and marrow transplant programs, serving children and young adults. Recognized as one of the top childhood cancer centers in the country by U.S. News & World Report, the Aflac Cancer and Blood Disorders Center cares for more than 500 newly diagnosed cancer patients and treats nearly 2,000 unique sickle cell disease patients each year. Ranked number one in the country for COG therapeutic clinical trial enrollment, our program offers patients access to more than 450 clinical trials, including 14 innovative Aflac Cancer and Blood Disorders Center investigator-initiated trials. Visit choa.org/cancer for more information.

* Required fields